IFIH1 and dermatomyositis: It was reported that patients with anti‐MDA5 antibody positive DM‐ILD were treated with rituximab, tofacitinib and pirfenidone,11 and the anti‐MDA5 antibody was transformed after 76 weeks of treatment.